539. GS-CA2: A Novel, Potent, and Selective First-In-class Inhibitor of HIV-1 Capsid Function Displays Nonclinical Pharmacokinetics Supporting Long-Acting Potential in HumansJim Zheng, Winston C. Tse, Scott D. Schroeder et al.|Open Forum Infectious Diseases|2018Cited by 15
Lenacapavir Exhibits Atropisomerism—Mechanistic Pharmacokinetics and Disposition Studies of Lenacapavir Reveal Intestinal Excretion as a Major Clearance PathwayJim Zheng, Raju Subramanian, Bing Lu et al.|Journal of Pharmacology and Experimental Therapeutics|2024Cited by 13
Discovery ofLenacapavir: First-in-Class Twice-YearlyCapsid Inhibitor for HIV-1 Treatment and Pre-exposure ProphylaxisEda Canales, John O. Link, Winston C. Tse et al.|Journal of Medicinal Chemistry|2025Cited by 11
Human pharmacokinetics prediction with an <i>in vitro</i>–<i>in vivo</i> correction factor approach and <i>in vitro</i> drug-drug interaction profile of bictegravir, a potent integrase-strand transfer inhibitor component in approved biktarvy<sup>®</sup> for the treatment of HIV-1 infectionRaju Subramanian, Bill J. Smith, Jianhong Wang et al.|Xenobiotica|2022Cited by 5
Intestinal Excretion is a Major Disposition Pathway of Lenacapavir in Rat and DogJim Zheng, Raju Subramanian, Winston C. Tse et al.|The FASEB Journal|2021Cited by 1